The Misuse of Drugs (Designation) (Amendment) Order (Northern Ireland) 2015
S.R. 2015/54 · Made 12 February 2015
Dangerous Drugs
Made 12th February 2015
Coming into operation 5th March 2015
The Department of Health, Social Services and Public Safety makes the following Order in exercise of the powers conferred by section 7(4) of the Misuse of Drugs Act 1971f1 as adapted by section 7(9) of that Act and now vested in itf2 and after consultation with the Advisory Council on the Misuse of Drugs in accordance with section 7(7) of that Act.
Annotations to the whole text
Footnotes
- f1
-
1971 c.38 as amended by s.151 of and Schedule 17 to the Police Reform and Social Responsibility Act 2011 c.13.
- f2
-
S.R.&O.(N.I.)1973 No.504, Article 5(a) and S.I.1999/283 (N.I.1), Article 3(6)
Contents
- 1Citation, commencement and interpretation
- 2Amendment to the Misuse of Drugs (Designation) Order (Northern Ireland) 2001
- Signature
- Explanatory note
1Citation, commencement and interpretation
This Order may be cited as the Misuse of Drugs (Designation) (Amendment) Order (Northern Ireland) 2015 and shall come into operation on 5th March 2015.
The Interpretation Act (Northern Ireland) 1954f1 shall apply to this Order as it applies to an Act of the Northern Ireland Assembly.
2Amendment to the Misuse of Drugs (Designation) Order (Northern Ireland) 2001
The Misuse of Drugs (Designation) Order (Northern Ireland) 2001f1 is amended as follows.
In paragraph 1(a) of Part 1 of the Schedule,
after “Tenocyclidine” insert—
“(6aR,9R)-4-acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (ALD-52)”
after “4-Bromo-2, 5-dimethoxy-a-methylphenethylamine” insert—
“3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921)
(6aR,9R)-N,N-diethyl-7-allyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (AL-LAD)
(6aR,9R)-N,N-diethyl-7-ethyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (ETH-LAD)
(6aR,9R)-N,N-diethyl-7-propyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (PRO-LAD)”
after “2-((Dimethylamino)methyl)-1-(3-hydroxyphenyl)cyclohexanol” insert—
“2,4-dimethylazetidinyl{(6aR,9R)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3- fg]quinolin-9-yl}methanone (LSZ)”
For paragraph 1(b) of Part 1 of the Schedule, substitute—
“(b)any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by modification in any of the following ways, that is to say—
(i)by substitution at the nitrogen atom of the side chain to any extent with alkyl or alkenyl substituents, or by inclusion of the nitrogen atom of the side chain (and no other atoms of the side chain) in a cyclic structure;
(ii)by substitution at the carbon atom adjacent to the nitrogen atom of the side chain with alkyl or alkenyl substituents;
(iii)by substitution in the 6-membered ring to any extent with alkyl, alkoxy, haloalkyl, thioalkyl, alkylenedioxy, or halide substituents;
(iv)by substitution at the 2-position of the tryptamine ring system with an alkyl substituent;”.
Signature
Sealed with the Official Seal of the Department of Health, Social Services and Public Safety on 12th February 2015
L.S.
Dr Paddy Woods
A senior officer of the
Department of Health, Social Services and Public Safety
Explanatory note
(This note is not part of the Order)
Section 7(3) of the Misuse of Drugs Act 1971 requires regulations to be made to allow the use for medical purposes of the drugs which are subject to control under that Act. Section 7(3) does not apply to any drug designated by order under section 7(4) as a drug to which section 7(4) is to apply. This Order amends the Misuse of Drugs (Designation) Order (Northern Ireland) 2001 by inserting the synthetic opiate (known as AH-7921) and LSD related compounds into Part 1 of the Schedule to that Order. This Order also replaces the definition of tryptamine compounds in Part 1 of the Schedule with a wider generic definition.